CLINICAL TRIALS PROFILE FOR LEVAMISOLE HYDROCHLORIDE

All Clinical Trials for levamisole hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002551 ↗	SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed	Completed	Cancer and Leukemia Group B	Phase 3	1994-03-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which treatment regimen is more effective for rectal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of combination chemotherapy plus radiation therapy in treating patients who have rectal cancer that has been surgically removed.
NCT00002551 ↗	SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed	Completed	Eastern Cooperative Oncology Group	Phase 3	1994-03-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which treatment regimen is more effective for rectal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of combination chemotherapy plus radiation therapy in treating patients who have rectal cancer that has been surgically removed.
NCT00002551 ↗	SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed	Completed	National Cancer Institute (NCI)	Phase 3	1994-03-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which treatment regimen is more effective for rectal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of combination chemotherapy plus radiation therapy in treating patients who have rectal cancer that has been surgically removed.
NCT00002551 ↗	SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed	Completed	NCIC Clinical Trials Group	Phase 3	1994-03-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which treatment regimen is more effective for rectal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of combination chemotherapy plus radiation therapy in treating patients who have rectal cancer that has been surgically removed.
NCT00002551 ↗	SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed	Completed	North Central Cancer Treatment Group	Phase 3	1994-03-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which treatment regimen is more effective for rectal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of combination chemotherapy plus radiation therapy in treating patients who have rectal cancer that has been surgically removed.

Clinical Trial Conditions for levamisole hydrochloride

Condition Name

Condition Name for levamisole hydrochloride
Intervention	Trials
Colorectal Cancer	6
Anemia, Hemolytic	3
Aplastic Anemia	2
Thrombosis	2

Condition MeSH

Condition MeSH for levamisole hydrochloride
Intervention	Trials
Colorectal Neoplasms	6
Anemia	5
Anemia, Aplastic	4
Syndrome	4

Clinical Trial Locations for levamisole hydrochloride

Trials by Country

Trials by Country for levamisole hydrochloride
Location	Trials
United States	49
China	8
Iran, Islamic Republic of	3
South Africa	2
Puerto Rico	2

Trials by US State

Trials by US State for levamisole hydrochloride
Location	Trials
Ohio	4
Wisconsin	3
Pennsylvania	3
Nebraska	3
Iowa	3

Clinical Trial Progress for levamisole hydrochloride

Clinical Trial Phase

Clinical Trial Phase for levamisole hydrochloride
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	14
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for levamisole hydrochloride
Clinical Trial Phase	Trials
Completed	12
Unknown status	8
Recruiting	6

Clinical Trial Sponsors for levamisole hydrochloride

Sponsor Name

Sponsor Name for levamisole hydrochloride
Sponsor	Trials
National Cancer Institute (NCI)	4
Institute of Hematology & Blood Diseases Hospital	3
The First Affiliated Hospital of Zhengzhou University	3

Sponsor Type

Sponsor Type for levamisole hydrochloride
Sponsor	Trials
Other	64
NIH	5
Industry	1

Levamisole hydrochloride Market Analysis and Financial Projection

Levamisole Hydrochloride: Clinical Trials, Market Analysis, and Projections

Introduction to Levamisole Hydrochloride

Levamisole hydrochloride is a drug with a diverse range of applications, from veterinary medicine to human health. Initially developed as an anthelmintic, it has been used to treat parasitic infections in animals and has also seen off-label use in various human health conditions.

Clinical Trials and Efficacy

Use in Nephrotic Syndrome

One of the significant clinical trials involving levamisole hydrochloride is its use in children with steroid-sensitive idiopathic nephrotic syndrome (SSINS). A randomized, double-blind, placebo-controlled trial demonstrated that levamisole significantly increases the time to relapse in these patients. The study, which included 99 patients from six countries, showed that between 100 days and 12 months after starting the treatment, the time to relapse was significantly longer in the levamisole group compared to the placebo group. By the end of the 12-month treatment period, 26% of patients in the levamisole group were still in remission, compared to 6% in the placebo group[1].

Use in Loiasis

Another clinical trial evaluated the safety and efficacy of levamisole in reducing microfilarial densities (MFDs) in individuals with loiasis, a parasitic infection caused by Loa loa. The trial, conducted in the Republic of the Congo, found that a single dose of 2.5mg/kg levamisole induced a promising transient reduction in MFDs. This dose was more effective than lower doses and showed a higher median reduction in MFDs at various time points post-treatment. However, it also caused more mild adverse events compared to the placebo group[4].

Safety and Side Effects

Adverse Events in Nephrotic Syndrome Treatment

In the context of SSINS, the most frequent serious adverse event associated with levamisole was asymptomatic moderate neutropenia, which was reversible either spontaneously or after treatment discontinuation. Regular blood controls are necessary to monitor for these safety issues[1].

Adverse Events in Loiasis Treatment

The trial on loiasis showed that while lower doses of levamisole (1.0mg/kg and 1.5mg/kg) were well-tolerated, the higher dose of 2.5mg/kg caused more mild adverse events. Despite this, the higher dose was effective in reducing MFDs[4].

General Safety Concerns

Levamisole hydrochloride has been associated with serious side effects, particularly when used in humans. Agranulocytosis, a condition characterized by a dangerously low number of white blood cells, is one of the significant safety concerns. These safety issues have led to restrictions on the drug's use in some markets[5].

Market Analysis

Current Market Size and Growth

The levamisole hydrochloride market has experienced rapid growth in recent years. The market size is expected to continue expanding from 2023 to 2031, driven by growth in both the agricultural and pharmaceutical sectors. The market is segmented based on type (25mg/tablet, 50mg/tablet) and application (hospital pharmacy, retail pharmacy), as well as geographical regions[2].

Key Drivers

1. Increased Livestock Population: The growing demand for meat and dairy products, especially in regions like Asia-Pacific and Latin America, has led to an increase in the livestock population. This, in turn, has increased the demand for levamisole hydrochloride for deworming in animals[5].

2. Applications in Cancer Immunotherapy: Levamisole hydrochloride has gained attention for its immunomodulatory effects, particularly in the treatment of colorectal cancer. This off-label use has contributed to the market's expansion[5].

Market Segmentation

The market is segmented based on:

• Type: 25mg/tablet and 50mg/tablet
• Application: Hospital pharmacy and retail pharmacy
• Geographical Regions: North America, Europe, Asia-Pacific, South America, and Middle-East and Africa[2].

Market Projections

Forecasted Growth

The levamisole hydrochloride market is anticipated to attain significant growth from 2023 to 2031. The positive momentum in market dynamics and the expected sustained expansion indicate robust growth rates throughout the forecasted period. The market is projected to undergo substantial development, driven by the increasing demand in both veterinary and pharmaceutical sectors[2].

Challenges and Opportunities

Despite the growth projections, the market faces challenges such as safety concerns and regulatory restrictions. The association of levamisole hydrochloride with serious side effects like agranulocytosis has led to restrictions in some markets, which could limit its potential. However, advancements in immunotherapy and the growing awareness of animal health present opportunities for further market expansion[5].

Regulatory Considerations

European Medicines Agency (EMA) Evaluation

The EMA has evaluated levamisole hydrochloride for various concerns, including visual distinguishability of different tablet strengths, content uniformity, dissolution, and stability data. The agency has also questioned the GCP compliance of pivotal studies and the lack of data on the drug's interaction potential with other medicinal products. These issues highlight the need for thorough regulatory compliance and additional research to address these concerns[3].

Key Takeaways

• Clinical Efficacy: Levamisole hydrochloride has shown efficacy in treating SSINS in children and reducing MFDs in loiasis.
• Safety Concerns: The drug is associated with serious side effects, including neutropenia and agranulocytosis.
• Market Growth: The market is expected to grow significantly from 2023 to 2031, driven by demand in veterinary and pharmaceutical sectors.
• Regulatory Considerations: Regulatory bodies have raised several concerns that need to be addressed to ensure the safe and effective use of levamisole hydrochloride.

FAQs

What is levamisole hydrochloride primarily used for?

Levamisole hydrochloride is primarily used as an anthelmintic in veterinary medicine to treat parasitic infections in animals. It also has off-label uses in human health, including the treatment of SSINS and potential applications in cancer immunotherapy.

What are the significant side effects associated with levamisole hydrochloride?

The drug is associated with serious side effects such as asymptomatic moderate neutropenia and agranulocytosis, a condition characterized by a dangerously low number of white blood cells.

How does levamisole hydrochloride affect nephrotic syndrome in children?

Levamisole hydrochloride has been shown to increase the time to relapse in children with SSINS and prevent recurrence during one year of treatment compared to prednisone alone.

What is the current market size and growth projection for levamisole hydrochloride?

The market size of levamisole hydrochloride is expected to grow significantly from 2023 to 2031, driven by growth in both the agricultural and pharmaceutical sectors.

What are the key drivers of the levamisole hydrochloride market?

Key drivers include the increased livestock population, rising demand for animal health products, and applications in cancer immunotherapy.

Sources

1. International Society of Nephrology: "A randomized clinical trial indicates that levamisole increases the time to relapse in children with steroid-sensitive idiopathic nephrotic syndrome" - PubMed.
2. Market Research Intellect: "Levamisole Hydrochloride Tablets Market Size, Scope And Forecast" - Market Research Intellect.
3. European Medicines Agency: "Withdrawal assessment report: Elmisol, INN-levamisole" - EMA.
4. Oxford University Press: "Safety and Efficacy of Levamisole in Loiasis: A Randomized, Double-Blind, Placebo-Controlled Trial" - Oxford Academic.
5. OpenPR: "Levamisole Hcl Market Showing Impressive Growth during Forecast by 2032" - OpenPR.